Skip to main content
. 2020 Mar 5;17(5):1710. doi: 10.3390/ijerph17051710

Figure 1.

Figure 1

The affordability of medicines in cardiovascular disease (CVD) therapeutic groups based on monotherapy treatment scenarios.